<![CDATA[FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease]]>
Read the full articleYou might also wanna read
US FDA approves MannKind's inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children reut.rs/4vfAOYh
Gene therapy for children with sickle cell disease approved by FDA
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration.
MATCH cohort provides regulatory-ready external control framework for MSUD gene therapy trials
Brigatti et al. develop MATCH, a prospective natural history cohort designed as a regulatory-ready external control for gene therapy trials
MATCH cohort provides regulatory-ready external control framework for MSUD gene therapy trials
Brigatti et al. develop MATCH, a prospective natural history cohort designed as a regulatory-ready external control for gene therapy trials
FDA Approves First Gene Therapy For Young Children With Sickle Cell Disease
The report said a clinical trial involving 15 children between the ages of 5 and 11 produced encouraging results.
FDA Scientists Find Insufficient Evidence for Peptides, Undercutting RFK Jr.'s Push for Expanded Access
RFK Jr. recently added peptide-friendly members to a key panel
medpagetoday.com·8d agoMedtronic Aktie: FDA-Offensive für Hugo
Medtronic bläst im lukrativen Markt für OP-Roboter zur Attacke. Der Medizintechnik-Konzern will die Einsatzbereiche seines Hugo-Systems mass
Comments
Sign in to join the conversation.
No comments yet. Be the first.